HPV Testing And Pap Test Market Analysis Report By Test Type, By Application, By Product, By Technology, By End Use, By Region And Segment Forecasts From 2021 To 2028

Synopsis

The global HPV testing and pap test market was prized by USD 1.7 billion in 2020. It is estimated to witness a 16.4% CAGR from 2021 to 2028.

Drivers

Greater occurrence of cervical cancer, scientific progression, and rising figure of cervical cancer screening plans are the few key factors, inspiring the enlargement of the market for HPV testing and pap test.

Rising demand for technically highly developed investigative measures for screening vaginal and cervical cancers is one of the fundamental reasons estimated to steer the market, during the forecast period.

Diverse scientific progression, for example, use of a variety of molecular markers in screening measures, the advancement of HPV-type 16 E7-specific human immunologic assays utilized in the non-HLA2 category, and cobas system endorsements, are the matters anticipated to power the market.

The increasing figure of alertness agendas, by diverse associations for screening cervical cancer, is one of the most important reasons estimated to impel the market, for the duration of the forecast.

Effect of Covid-19

The eruption of the COVID-19 pandemic and countrywide lockdowns caused by it in major geographies has significantly abridged the usual screening actions of cervical cancer. In line with the information published through the CDC, because of cautious instructions, the screening percentage for cervical cancer reduced by roughly 80.0% in California, the U.S. Therefore, such reduced testing percentages have harmfully influenced the expansion of the general revenue in the market, during 2020.

Technology Insight

In 2020, the other technologies section held the major, 47.9% revenue share and led the HPV testing and pap test market. This big share can be credited to the greater acceptance of cystoscopy and colposcopy procedures in screenings of HPV and cervical cancer. The other technologies section comprises cystoscopy and colposcopy.

Conversely, the PCR section is likely to observe the highest development in the technology sector, because of the realization of novel rules to make use of DNA HPV testing processes, owing to its enhanced exactness plus the price efficiency.

Product Insight

The consumables sector held the biggest, 65.7% revenue share and led the HPV testing and pap test market, in 2020, because of its recurring practice in HPV and cervical screenings. Besides, incessant expansion actions by the major companies working in the market, in addition to the presentation of novel consumables like assays & kits, for extra precise analysis of HPV and Pap, are projected to enhance the progress of the sector.

The services sector is likely to observe the highest CAGR, for the duration of the forecast, due to the initiation of personal and comfortable HPV screening services to augment the rate of cervical cancer screening in important marketplaces.

Application Insight

In 2020, the cervical cancer screening division held the biggest, 75.7% revenue share and led the HPV testing and pap test market. The division is anticipated to observe a 16.9% CAGR throughout the forecast period. In a contrast to vaginal cancer, the greater frequency of cervical cancer is expected to speedy enlargement and the domination of cervical cancer screening. In addition, incessant programs of public-private institutes to boost the frequency of cervical cancer screening are, furthermore, likely to maintain the growth of the division.

In contrast, the vaginal cancer screening division is estimated to observe a 14.4% CAGR for the period of the forecast. Rising occurrence, as well as elevated death rates of vaginal cancer, has pushed the demand for efficient screening tests.

Test Type Insight

On account of its extensive realization in screening programs, the pap test section held the 64.0% revenue share and led the HPV testing and pap test market, in 2020. Rising projects to enhance alertness regarding the pap tests are, furthermore, anticipated to stimulate the expansion of the sector.

Owing to the rising government advice to utilize additional competent HPV screenings in addition to the commercialization of modern tests, the HPV testing section is expected to observe 17.6% CAGR, during the forecast period.

End-Use Insight

The hospitals & clinics section held the biggest, 44.5% revenue share and led the market, in 2020, because they function like main care settings for the judgment as well as healing of every sickness, which includes cervical cancer and HPV infections.

The other section is projected to illustrate the highest development within the end-use section, due to the rising utilization of the POC tests in-home treatment situation. Current progressions in the POC test kits have given rise to shorter rotational times and mistake-free outcomes. This is estimated to improve the market, during the forecast years.

Regional Insight

In 2020, North America detained the major, 41.1% revenue share and led the global HPV testing and pap test market. It is expected to continue the advantage, all through the forecast period.

The constructive situation of healthcare compensation, greater alertness regarding before-time identification of cervical cancer, and entrenched rules for screening are the things, pushing the enlargement of the market, within the region. Besides, greater access to technically superior services as well as the products, better affordability, and elevated acceptance, have additionally increased expansion of the market, within the region.

Moreover, the attendance of important companies in the local marketplace along with the constant tactical plans, taken on by them has considerably maintained the development of the market, within the region.

The Asia Pacific market for HPV testing and a pap test is anticipated to demonstrate an exceptional CAGR, throughout the forecast period. The greater commonness of HPV and cervical cancer in important nations, like India, Japan and China can be credited to the superior development of the market, within the region. The scientific progression in the Asia Pacific area is, moreover, expected to power the enlargement of the market, throughout the forecast period.

Additionally, tactical plans taken on by the public-private groups, to enhance cervical cancer screening within this state, are one of the most important factors anticipated to help escalation for the period of the forecast.

Companies

The major companies are busy implementing the inorganic and natural enlargement policies such as geological growth, development of innovative products, and mergers & acquisitions to take over bigger market shares.

Some of the companies for HPV testing and pap test market are:

    • bioMérieux SA
    • Seegene, Inc.
    • Arbor Vita Corporation
    • F. Hoffmann-La Roche
    • Quest Diagnostics, Inc.
    • Qiagen N.V.
    • Thermo Fisher Scientific, Inc.
    • NURX, Inc.
    • Femasys, Inc.
    • Hologic, Inc.
    • Becton, Dickinson and Company
    • Abbott Laboratories

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Million Insights has segmented the global HPV testing and Pap test market report on the basis of test type, application, product, technology, end-use, and region:

• Test Type Outlook (Revenue, USD Million, 2016 - 2028)
    • HPV Testing
    • Pap Test

• Application Outlook (Revenue, USD Million, 2016 - 2028)
    • Cervical Cancer Screening
    • Vaginal Cancer Screening

• Product Outlook (Revenue, USD Million, 2016 - 2028)
    • Instruments
    • Consumables
    • Services

• Technology Outlook (Revenue, USD Million, 2016 - 2028)
    • PCR
    • Immunodiagnostics
    • Other Technologies

• End-use Outlook (Revenue, USD Million, 2016 - 2028)
    • Hospitals & Clinics
    • Laboratories
    • Other End Users

• Regional Outlook (Revenue, USD Million, 2016 - 2028)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
    • The Asia Pacific
        • Japan
        • China
        • India
        • South Korea
        • Australia
        • Singapore
    • Latin America
        • Brazil
        • Mexico
        • Argentina
    • MEA
        • South Africa
        • Saudi Arabia
        • UAE